AU741258B2 - MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions - Google Patents

MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions Download PDF

Info

Publication number
AU741258B2
AU741258B2 AU42613/97A AU4261397A AU741258B2 AU 741258 B2 AU741258 B2 AU 741258B2 AU 42613/97 A AU42613/97 A AU 42613/97A AU 4261397 A AU4261397 A AU 4261397A AU 741258 B2 AU741258 B2 AU 741258B2
Authority
AU
Australia
Prior art keywords
muc
derivative
disease
cells
icam
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU42613/97A
Other languages
English (en)
Other versions
AU4261397A (en
Inventor
Judith C. Hugh
B. Michael Longenecker
Lyle H. Regimbald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncothyreon Canada Inc
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of AU4261397A publication Critical patent/AU4261397A/en
Application granted granted Critical
Publication of AU741258B2 publication Critical patent/AU741258B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
AU42613/97A 1996-09-10 1997-09-10 MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions Ceased AU741258B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2571896P 1996-09-10 1996-09-10
US60/025718 1996-09-10
PCT/US1997/015928 WO1998010783A1 (fr) 1996-09-10 1997-09-10 Le muc-1, agent therapeutique immunosuppresseur traitant les etats inflammatoires et auto-immunitaires

Publications (2)

Publication Number Publication Date
AU4261397A AU4261397A (en) 1998-04-02
AU741258B2 true AU741258B2 (en) 2001-11-29

Family

ID=21827678

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42613/97A Ceased AU741258B2 (en) 1996-09-10 1997-09-10 MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions

Country Status (5)

Country Link
EP (1) EP0925071A4 (fr)
JP (1) JP2001501599A (fr)
AU (1) AU741258B2 (fr)
CA (1) CA2264748A1 (fr)
WO (1) WO1998010783A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502907A (ja) * 1996-10-25 2001-03-06 ダナ―ファーバー キャンサー インスティテュート インク． ムチンが介在した免疫調節
WO2000034468A2 (fr) * 1998-12-11 2000-06-15 Biomira Inc. Antagonistes de la muc-1 et methodes de traitement de troubles immunitaires
DE10056136A1 (de) * 2000-11-07 2002-05-16 Nemod New Modalities Verwendung von Schwangerschaftsproteinen, Liposomen, nativen Muzin-Fragmenten und Mimikry-Verbindungen zur Behandlung und Prophylaxe von entzündlichen Erkrankungen, zur Verhinderung der Metastasierung und zur Prophylaxe von Tumorerkrankungen
WO2002062319A2 (fr) * 2001-01-19 2002-08-15 Corixa Corporation Administration sous forme de microspheres de peptides de mucine
AU2003266236A1 (en) 2002-07-22 2004-02-09 Nemod Immuntherapie Ag Method for the production of an immunostimulating mucin (muc1)
US9095551B2 (en) 2009-01-29 2015-08-04 Riken Combined preparation for treating joint diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003825A1 (fr) * 1993-07-30 1995-02-09 Finn Olivera J Peptides synthetiques a repetitions en tandem multiples, a base de mucine et d'analogues, et utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001502907A (ja) * 1996-10-25 2001-03-06 ダナ―ファーバー キャンサー インスティテュート インク． ムチンが介在した免疫調節

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003825A1 (fr) * 1993-07-30 1995-02-09 Finn Olivera J Peptides synthetiques a repetitions en tandem multiples, a base de mucine et d'analogues, et utilisations

Also Published As

Publication number Publication date
JP2001501599A (ja) 2001-02-06
CA2264748A1 (fr) 1998-03-19
AU4261397A (en) 1998-04-02
EP0925071A1 (fr) 1999-06-30
EP0925071A4 (fr) 2000-09-13
WO1998010783A1 (fr) 1998-03-19

Similar Documents

Publication Publication Date Title
Benichou et al. Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection.
Kamada et al. Reversal of transplantation immunity by liver grafting
AU709711B2 (en) Methods for modulating T cell unresponsiveness
Multhoff et al. Cell surface expression of heat shock proteins and the immune response
Benjamin et al. Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination
Rollins et al. Evidence that activation of human T cells by porcine endothelium involves direct recognition of porcine SLA and costimulation by porcine ligands for LFA-1 and CD2
Khoury et al. Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat.
Arima et al. Inhibition by CTLA4Ig of experimental allergic encephalomyelitis.
Briscoe et al. Human endothelial cell costimulation of T cell IFN-gamma production.
WO1993006866A2 (fr) Procede prophylactique ou therapeutique de maladies de la peau causees par des cellules presentant des antigenes au moyen d'inhibiteurs de l'interaction entre cd2 et lfa-3
AU673985B2 (en) CD8 binding domain peptides
Schendel et al. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy
AU741258B2 (en) MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
Fisk et al. Changes in an HER-2 peptide upregulating HLA-A2 expression affect both conformational epitopes and CTL recognition: implications for optimization of antigen presentation and tumor-specific CTL induction
Pattison et al. New insights into mechanisms of allograft rejection
EP0630255A1 (fr) Conjugues cmh permettant de traiter l'auto-immunite
US20020044943A1 (en) MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
Aiello et al. A role for cytokines in antigen presentation: IL-1 and IL-4 induce accessory functions of antigen-presenting cells.
Aragnol et al. Endocytosis of MHC molecules by B cell-B lymphoma and B cell-T lymphoma hybrids.
Tovey et al. Role of the type I interferons in allograft rejection
Dirienzo et al. α1-Acid glycoprotein (α1-AGP) on the membrane of human lymphocytes: possible involvement in cellular activation
CA2194550A1 (fr) Compositions a chaines invariables utiles dans le traitement de maladies auto-immunes
CA2307622A1 (fr) Derives de muc-1 et leur utilisation pour traiter l'immuno-depresseur induite par mucine muc-1 et associee au cancer
Mitchell et al. Analysis and reversal of the inhibition of cytophilic antibody receptors produced by antibody
AU2006202939B2 (en) Methods of modulating T cell unresponsiveness

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired